Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05292755 · ClinicalTrials.gov registry record · Phase 4
Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT05292755 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 80 participants.
The verdict
NCT05292755, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
Carboxymethylcellulose (CMC), a common component in artificial tears, has been shown to modify the gut microbiome. The study is examining its effects on the eye microbiome, which may have implications on ocular disease and artificial tear choice. The study will administer artificial tears containing CMC to the treatment group and artificial tears without CMC to the control group. Surveys and conjunctival swabs will be collected before and after treatment for bacterial genome sequencing and analyzed by R statistical packages.
Interventions
- DRUG Carboxymethylcellulose (CMC) Artificial Tears
- DRUG Preservative-free, CMC-free Artificial Tears (control)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2022-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05292755
The ClinicalTrials.gov registry entry for NCT05292755 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboxymethylcellulose (CMC) Artificial Tears is the first listed.
NCT05292755 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05292755 about?
NCT05292755 is a clinical study titled "Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome". Carboxymethylcellulose (CMC), a common component in artificial tears, has been shown to modify the gut microbiome. The study is examining its effects on the eye microbiome, which may have implications on ocular disease and artificial tear choice. The study will administer artificial tears containing...
What is the current status of trial NCT05292755?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2022-04-22. Estimated completion is 2022-07-01.
What interventions are being tested in trial NCT05292755?
The interventions under investigation include: Carboxymethylcellulose (CMC) Artificial Tears (DRUG), Preservative-free, CMC-free Artificial Tears (control) (DRUG).
Who is sponsoring clinical trial NCT05292755?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.